On June 8, JD Health fell 3.85% in regular trading, trading at HK$36.84/share, with trading volume of HK$139 million. The decline came amid continued regulatory headwinds affecting the broader internet healthcare sector.

On the policy front, the National Medical Products Administration recently implemented the Compliance Guidelines for Online Retail of Prescription Drugs, mandating that prescription reviews must be completed by licensed pharmacists, explicitly banning AI-assisted prescription approvals, and prohibiting the display of prescription drugs on homepage or promotion through giveaways and livestreaming. Testing has confirmed that high-demand GLP-1 weight-loss injections can no longer be directly purchased online on major platforms including JD Health, with online sales pathways already adjusted. JD Health staff have confirmed that such medications now require offline pickup with valid prescriptions.

The broader Internet and Direct Marketing Retail sector declined in tandem, with Meituan down 4.06%, Ali Health down 3.06%, Ping An Good Doctor down 2.85%, Alibaba down 2.86%, and JD Group down 1.47%. Despite the company announcing a share buyback authorization of up to 10% of issued shares and executing a HK$8.5 million repurchase on June 5, sustained regulatory pressure has continued to outweigh supportive corporate actions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)